|Bid||2.9500 x 1300|
|Ask||2.8800 x 900|
|Day's Range||2.8500 - 3.1200|
|52 Week Range||1.5030 - 6.8300|
|Beta (5Y Monthly)||1.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 12, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||5.70|
cbdMD, Inc. (NYSE American: YCBD, YCBDpA) (the "Company"), one of the leading, and most highly trusted and recognized cannabidiol (CBD) company, announced today that its recently formed subsidiary, cbdMD Therapeutics, has begun a collaboration with researchers at the Colorado State University (CSU) veterinary program, to explore the effects of the Company’s patent pending, proprietary cbdMD branded cannabinoid blend on dogs that suffer from osteoarthritis. The results from this study will provid
cbdMD, Inc. (NYSE American: YCBD, YCBDpA), one of the nation’s leading and most highly trusted and recognized cannabidiol (CBD) brands, today announced its financial results and its business highlights for its second quarter and six months ended March 31, 2021.
NEW YORK, NY / ACCESSWIRE / May 12, 2021 / cbdMD, Inc. (AMEX:YCBD) will be discussing their earnings results in their 2021 Second Quarter Earnings call to be held on May 12, 2021 at 4:15 PM Eastern Time.